Surgical Outcome Results from SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX vs. Gemcitabine/nab-Paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma

OBJECTIVE: The optimal neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma (PDA) and the impact on surgical outcomes remains unclear. METHODS: S1505 (NCT02562716) was a randomized phase II study of perioperative chemotherapy with mFOLFIRINOX (Arm 1) or gemcitabine/nab-paclitaxel (Arm...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Ann Surg
Auteurs principaux: Ahmad, Syed A., Duong, Mai, Sohal, Davendra P. S., Gandhi, Namita S., Beg, M. Shaalan, Wang-Gillam, Andrea, Wade, James L., Chiorean, E. Gabriela, Guthrie, Katherine A., Lowy, Andrew M., Philip, Philip A., Hochster, Howard S.
Format: Artigo
Langue:Inglês
Publié: 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7856053/
https://ncbi.nlm.nih.gov/pubmed/32740235
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/SLA.0000000000004155
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires